Visceral leishmaniasis affects liver and spleen concentrations of amphotericin B following administration to mice

Journal of Antimicrobial Chemotherapy

Volumn 65, Issue 3, 2009, Pages 535-537

  Gershkovich, Pavel ^a   Wasan, Ellen K ^a,b   Sivak, Olena ^a   Li, Raymond ^a   Zhu, Xiaohua ^c   Werbovetz, Karl A ^c   Tidwell, Richard R ^d   Clement, John G ^e   Thornton, Sheila J ^a   Wasan, Kishor M ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b BRITISH COLUMBIA INSTITUTE OF TECHNOLOGY   (Canada)

^c OHIO STATE UNIVERSITY   (United States)

^d UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^e ICo Therapeutics Inc   (Canada)

Author keywords

Biodistribution; Disease states; Macrophages; Pharmacokinetics; Reticuloendothelial system

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; ICO 009; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BAGG ALBINO MOUSE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG SCREENING; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; LIVER; MOUSE; NONHUMAN; SINGLE DRUG DOSE; SPLEEN; VISCERAL LEISHMANIASIS;

ADMINISTRATION, ORAL; AMPHOTERICIN B; ANIMALS; ANTIPROTOZOAL AGENTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FEMALE; INJECTIONS, INTRAVENOUS; LEISHMANIASIS, VISCERAL; LIVER; MICE; MICE, INBRED BALB C; SPLEEN;

EID: 77950305712     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkp465     Document Type: Article

References (10)

1. Chappuis F, Sundar S, Hailu A et al. Visceral leishmaniasis: what are the needs for diagnosis, treatment and control? Nat Rev Microbiol 2007; 5: 873-82.
2. Malla N, Mahajan RC. Pathophysiology of visceral leishmaniasis-some recent concepts. Indian J Med Res 2006; 123: 267-74.
3. Singh RK, Pandey HP, Sundar S. Visceral leishmaniasis (kala-azar): challenges ahead. Indian J Med Res 2006; 123: 331-44.
4. Wasan EK, Bartlett K, Gershkovich P et al. Development and characterization of oral lipid-based amphotericin B formulations with enhanced drug solubility, stability and antifungal activity in rats infected with Aspergillus fumigatus or Candida albicans. Int J Pharm 2009; 372: 76-84.
5. Gershkovich P, Wasan EK, Lin M et al. Pharmacokinetics and biodistribution of amphotericin B in rats following oral administration in a novel lipid-based formulation. J Antimicrob Chemother 2009; 64: 101-8.
6. Wasan KM, Wasan EK, Gershkovich P et al. Highly effective oral amphotericin B formulation against murine visceral leishmaniasis. J Infect Dis 2009; 200: 357-60.
7. Gradoni L, Davidson RN, Orsini S et al. Activity of liposomal amphotericin B (AmBisome) against Leishmania infantum and tissue distribution in mice. J Drug Target 1993; 1: 311-6.
8. Olivier M, Tanner CE. Susceptibilities of macrophage populations to infection in vitro by Leishmania donovani. Infect Immun 1987; 55: 467-71.
9. Lim HJ, Parr MJ, Masin D et al. Kupffer cells do not play a role in governing the efficacy of liposomal mitoxantrone used to treat a tumor model designed to assess drug delivery to liver. Clin Cancer Res 2000; 6: 4449-60.
10. van Etten EW, Otte-Lambillion M, van Vianen W et al. Biodistribution of liposomal amphotericin B (AmBisome) and amphotericin B-desoxycholate (Fungizone) in uninfected immunocompetent mice and leucopenic mice infected with Candida albicans. J Antimicrob Chemother 1995; 35: 509-19.